Citations

Clear

31 citation(s) found for "Lieu, Christopher".

The Volume-Outcome Effect Calls for Centralization of Care in Esophageal Adenocarcinoma: Results From a Large National Cancer Registry
Han, Samuel , Hosokawa, Patrick , Friedman, Chloe , Fox, Charlie, Scott, Frank I. , Vajravelu, Ravy K. , McCarter, Martin D. , Cook, Michael B. , Gleisner, Ana , Katzka, David A. , Wani, Sachin , Kolb, Jennifer M. , Lieu, Christopher H. , Murphy, Caitlin C. , Falk, Gary W. , Scott, Frank I

Mayo Clinic

American Journal of Gastroenterology | November 23, 2020 | Volume: 116 | Issue: 4 | Pages: 811-815

10.14309/ajg.0000000000001046 | PMID 33982952 Get It

INTRODUCTION: Using the National Cancer Database, we assessed the relationship between facility overall esophageal adenocarcinoma (EAC) case volume and survival. METHODS: We categorized facilities into volume quintiles based on annual EAC patient volume and performed a multivariable Cox proportional hazards regression between facility patient volume and survival. RESULTS: In a cohort of 116,675 patients, facilities with higher vs lower (≥25 vs 1–4 cases) annual EAC patient volume demonstrated improved survival (adjusted hazard ratio: 0.80. 95% confidence interval: 0.70–0.91). DISCUSSION: This robust volume-outcome effect calls for centralization of care for EAC patients at high annual case volume facilities.
Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced-stage colorectal cancer (CRC-MRD Consortia).
Starr, Jason S. , Loranger, Kate, Westbrook, Laura, Krinshpun, Shifra , Hook, Nicole , Billings, Paul R. , Aleshin, Alexey , Kasi, Pashtoon Murtaza , Dayyani, Farshid , Morris, Van K. , Kopetz, Scott , Parikh, Aparna R. , Cohen, Stacey A. , Grothey, Axel , Lieu, Christopher H. , O’Hara, Mark H. , Sharma, Shruti , Zimmermann, Bernhard G

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 4108-4108

10.1200/jco.2020.38.15_suppl.4108 Get It

4108 Background: Circulating tumor DNA (ctDNA) testing can be used for the assessment of molecular residual disease (MRD) in patients with early-stage or advanced colorectal cancer (CRC). Prospective evaluation of this methodology in clinical practice has been limited to-date. Methods: A personalized and tumor-informed multiplex PCR assay (Signatera 16-plex bespoke mPCR NGS assay) was used for the detection and quantification of ctDNA for MRD assessment. We analyze and present results from an ongoing early adopter program of ctDNA testing across the spectrum of CRC management. Results: Here we present a total of 250 patients with colon (n=200), rectal (n=40), and other lower gastrointestinal cancers (n =10; anal, appendiceal, small bowel). MRD positivity rates and ctDNA quantification (mean tumor molecules/mL) are shown in Table. ctDNA detection was significantly associated with stage of disease (p<0.0001 Chi-square: 70.33). Additionally, in patients with radiologically measurable active metastatic disease, ctDNA detection rate was 100%. On the contrary, patients with advanced/metastatic disease who had partial response to treatment or no evidence of disease (NED) showed 28.5% and 19.2% of ctDNA-positivity, respectively. Conclusions: This is the first large, real-world study reporting on the results from a clinically validated MRD assay. For the first time we delineate MRD rates and quantify ctDNA concentration in patients with early-stage and advanced CRC. Furthermore, we provide an initial readout that effective ongoing treatment in patients with CRC may be correlated with ctDNA clearance. Ongoing analysis expanded to a cohort of 1200 clinical cases including correlation with genomic and serial testing will be presented. [Table: see text]
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
Mody, Kabir , Levasseur, Alexandra, Dhanarajan, Asha , Innocenti, Federico , Behrens, Robert J. , Peters, Walter R., Sommer, Nicolas, Sinicrope, Frank A. , Ou, Fang‐Shu , Zemla, Tyler , Nixon, Andrew B. , Dueck, Amylou C. , Lieu, Christopher H. , Cohen, Deirdre J , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e15169-e15169

10.1200/jco.2019.37.15_suppl.e15169 Get It

e15169 Background: In metastatic colorectal cancer with deficient DNA mismatch repair (dMMR), anti-PD-1 antibody monotherapy produced high tumor response rates and extended progression-free survival compared to lack of benefit for cancers with proficient MMR. In an ongoing phase III randomized trial, we will determine if the addition of the anti-PD-L1 antibody, atezolizumab (Genentech), to adjuvant FOLFOX can improve patient disease-free survival (DFS) vs FOLFOX alone in patients with stage III colon cancers with dMMR. By blocking the PD-1/PD-L1 interaction, atezolizumab may activate T cells, thereby, restoring their ability to detect and attack tumor cells. Limited data suggest that FOLFOX may increase intratumoral cytotoxic CD8+ T cells that could serve as ‘immune priming'. Methods: Patients with curatively resected stage III colon carcinomas with evidence of dMMR are randomized to modified FOLFOX6 for 6 months (12 cycles) alone (control arm) or combined with atezolizumab (840 mg IV q2 wk) with continuation of the antibody as monotherapy for an additional 6 months (total duration of 12 months) [experimental arm]. Patients will be stratified by T, N stage and tumor sidedness. Local testing for MMR proteins is allowed. Atezolizumab must begin by/with cycle 2. One cycle of FOLFOX is allowed pre-registration. The targeted accrual goal of 700 patients and 165 disease-free survival (DFS) events will provide 90% power to detect an effect size expressed as hazard ratio of 0.6 for the primary endpoint of DFS at two-sided alpha of 0.05. Interim analyses are planned at 50% and 75% of events. Secondary endpoints include overall survival, treatment tolerability, and quality of life. Results: This study is being conducted by the Alliance for Clinical Trials in Oncology, was approved by NCI CTEP and activated in 09/2017. The study is actively accruing and, as of 02/11/2019, 152 patients are enrolled. We are actively exploring an international collaboration. Conclusions: This is a current clinical trial in progress. Clinical trial information: NCT02912559.
A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).
Weekes, Colin D. , Lamberts, Laetitia E., Voortman, Johannes, Yue, Huibin, Scales, Suzie J. , Samineni, Divya , Wood, Katie, Brunstein, Flávia, Maslyar, Daniel, Kim, George P., Borad, Mitesh J. , McWilliams, Robert R. , Diamond, Jennifer R. , Vries, Elisabeth G.E. de , Verheul, Henk M.W. , Lieu, Christopher H. , Wang, Yulei

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2529-2529

10.1200/jco.2014.32.15_suppl.2529 Get It

Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502).
Mody, Kabir , Levasseur, Alexandra, Dhanarajan, Asha , Innocenti, Federico , Behrens, Robert J. , Peters, Walter R., Sommer, Nicolas, Sinicrope, Frank A. , Ou, Fang‐Shu , Shi, Qian , Nixon, Andrew B. , Dueck, Amylou C. , Lieu, Christopher H. , Cohen, Deirdre J , Sargent, Daniel J. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS3630-TPS3630

10.1200/jco.2017.35.15_suppl.tps3630 Get It

TPS3630 Background: In metastatic colorectal cancer with deficient DNA mismatch repair (MMR), anti-PD-1 antibody monotherapy produced high tumor response rates and extended progression-free survival compared to lack of benefit for proficient MMR tumors (Le, M, et al, NEJM 2016). We propose a phase III randomized trial to determine if the addition of the anti-PD-L1 antibody, atezolizumab (Genentech™), to adjuvant FOLFOX can improve patient disease-free survival (DFS) vs FOLFOX alone in patients with stage III colon cancers with dMMR or microsatellite instability (MSI). By blocking the PD-1/PD-L1 interaction, atezolizumab may activate T cells, thereby, restoring their ability to detect and attack tumor cells. Limited data suggest that FOLFOX may increase intratumoral cytotoxic CD8+ T cells that may serve as ‘immune priming.’ Methods: Patients with curatively resected stage III colon carcinomas with evidence of dMMR or MSI will be randomized to modified FOLFOX6 for 6 months (12 cycles) alone or combined with atezolizumab (840 mg IV q2 wk) continued as monotherapy for an additional 6 months (total duration of 12 months). Patients will be stratified by T, N stage and tumor sidedness. Local testing for MSI or MMR proteins is allowed. Atezolizumab must begin by/with cycle 2. The targeted accrual goal of 700 patients provides 90% power to detect an effect size expressed as hazard ratio of 0.6 for the primary endpoint DFS at two-sided alpha of 0.05. Interim analyses are planned at 50% and 75% of events. Secondary endpoints include overall survival, treatment tolerability, and quality of life. This study will be conducted by the Alliance for Clinical Trials in Oncology. The protocol has been approved by NCI CTEP and is expected to be activated in mid 2017. Clinical trial information: NCT02912559.
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline Summary From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Sepulveda, Antonia R. , Allegra, Carmen J. , Grody, Wayne W., Cushman‐Vokoun, Allison M. , Funkhouser, William K., Kopetz, Scott , Lindor, Noralane M. , Minsky, Bruce D. , Monzon, Federico A. , Singh, Veena , Clark, Jennifer , Colasacco, Carol , Temple‐Smolkin, Robyn , Ventura, Christina B., Nowak, Jan A. , Hamilton, Stanley R. , Grody, Wayne, Cushman-Vokoun, Allison M, Kopetz, Scott E, Singh, Veena M, Temple-Smolkin, Robyn, Lieu, Christopher H. , Sargent, Daniel J. , Willis, Joseph , Rumble, R. Bryan , Kopetz, Scott

Mayo Clinic

Journal of Oncology Practice | March 28, 2017 | Volume: 13 | Issue: 5 | Pages: 333-337

10.1200/jop.2017.022152 | PMID 28350513 Get It

A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).
Krishnamurthy, Anuradha , Stein, Mark N. , Sanoff, Hanna K. , Lee, James J. , Hansen, Aaron R. , Malhotra, Usha , Rippke, Sarah, Davis, S. Lindsey , Messersmith, Wells A. , Eckhardt, S. Gail, Dasari, Arvind , Lockhart, A. Craig , Bekaii‐Saab, Tanios , Yao, James C. , Meric‐Bernstam, Funda , Lieu, Christopher H. , Sanoff, Hanna , Hansen, Aaron R

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 609-609

10.1200/jco.2017.35.4_suppl.609 Get It

609 Background: Targeting MEK is of interest in the development of novel agents for treatment of many malignancies. However, better strategies are needed to overcome acquired resistance to MEK inhibitors. Preclinical studies have shown Wnt pathway overexpression in KRAS mutant cell lines resistant to the MEK inhibitor, Selumetinib. The combination of selumetinib and cyclosporin A (CsA), a non-canonical WnT pathway modulator, demonstrated antitumor activity in patient-derived xenograft (PDX) models. We are conducting an NCI CTEP-approved Phase I/IB trial (NCI # 9571/COMIRB # 13-2628) of selumetinib and CsA combination. Biomarkers of response to therapy are being co-developed. We hypothesize that this combination will be safe and potentially effective in patients with mCRC and that upregulation of FZD2 may predict for sensitivity. Methods: Phase I trial with initial dose escalation investigating the combination of selumetinib and CsA in patients with advanced solid tumors (n = 18) followed by an expansion cohort in patients with irinotecan and oxaliplatin-refractory mCRC (n = 20). The expansion cohort utilizes a selumetinib “run-in” to evaluate efficacy in RAS-WT and RAS-MT mCRC to identify those patients most likely to respond to the combination. Results: 18 patients were enrolled in the dose escalation phase and 10 patients have been enrolled in the dose expansion phase as of September 2016. Grade 1 or 2 nausea and rash were reported as the most common AEs. Most commonly reported Grade 3 or 4 toxicities were hypertension, elevated liver enzymes and rash. Three DLTs were reported with Grade 3 hypertension noted at dose level 1 and 2 and grade 3 rash reported at dose level 2. The maximum tolerated dose was defined as Selumetinib 75 mg BID and CsA 2 mg/kg BID on a 28-day cycle. Two partial responses and sixteen stable disease responses have been observed. Six patients have exhibited progressive disease. Conclusions: Selumetinib in combination with cyclosporin A appears to be well-tolerated with evidence of activity in solid tumors. Expansion cohort will complete enrollment this month. Clinical trial information: NCT02188264.
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, Antonia R. , Allegra, Carmen J. , Grody, Wayne W., Cushman‐Vokoun, Allison M. , Funkhouser, William K., Kopetz, Scott , Lindor, Noralane M. , Minsky, Bruce D. , Monzon, Federico A. , Singh, Veena , Clark, Jennifer , Colasacco, Carol , Temple‐Smolkin, Robyn , Ventura, Christina B., Nowak, Jan A. , Hamilton, Stanley R. , Lieu, Christopher H. , Sargent, Daniel J. , Willis, Joseph , Rumble, R. Bryan , Kopetz, Scott

Mayo Clinic

American Journal of Clinical Pathology | February 6, 2017 | Volume: 147 | Issue: 3 | Pages: 221-260

10.1093/ajcp/aqw209 | PMID 28165529 Get It

Abstract Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Sepulveda, Antonia R. , Allegra, Carmen J. , Grody, Wayne W., Cushman‐Vokoun, Allison M. , Funkhouser, William K., Kopetz, Scott , Lindor, Noralane M. , Minsky, Bruce D. , Monzon, Federico A. , Singh, Veena , Clark, Jennifer , Temple‐Smolkin, Robyn , Ventura, Christina B., Nowak, Jan A. , Hamilton, Stanley R. , Lieu, Christopher H. , Sargent, Daniel J. , Willis, Joseph , Colasacco, Carol , Rumble, R. Bryan , Kopetz, Scott

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 6, 2017 | Volume: 141 | Issue: 5 | Pages: 625-657

10.5858/arpa.2016-0554-cp | PMID 28165284 Get It

Objectives.— To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods.— The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results.— Twenty-one guideline statements were established. Conclusions.— Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.
Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Weekes, Colin D. , Lamberts, Laetitia E., Voortman, Johannes, Diamond, Jennifer R. , Vries, Elisabeth G.E. de , Verheul, Henk M.W. , Kim, George P., Wang, Yulei , Scales, Suzie J. , Samineni, Divya , Brunstein, Flávia, Choi, YounJeong, Maslyar, Daniel, Colón‐Otero, Gerardo , McWilliams, Robert R. , Borad, Mitesh J. , Lieu, Christopher H. , de Vries, Elisabeth G E

Mayo Clinic

Molecular Cancer Therapeutics | January 29, 2016 | Volume: 15 | Issue: 3 | Pages: 439-447

10.1158/1535-7163.mct-15-0693 | PMID 26823490 Get It

Abstract DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2–2.8 mg/kg; q3w) or weekly (0.8–1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase II dose (RP2D) to evaluate safety and pharmacokinetics. Antitumor response was evaluated per RECIST 1.1 and serum CA19-9 or CA125 declines. Tumor mesothelin expression was determined by IHC. Seventy-one patients (40 pancreatic cancer; 31 ovarian cancer) were treated with DMOT4039A. For the q3w schedule (n = 54), the MTD and RP2D was 2.4 mg/kg, with dose-limiting toxicities of grade 3 hyperglycemia and grade 3 hypophosphatemia at 2.8 mg/kg. For the weekly schedule (n = 17), the maximum assessed dose was 1.2 mg/kg, with further dose escalations deferred because of toxicities limiting scheduled retreatment in later cycles, and therefore the RP2D level for the weekly regimen was determined to be 1 mg/kg. Across both schedules, the most common toxicities were gastrointestinal and constitutional. Treatment-related serious adverse events occurred in 6 patients; 4 patients continued treatment following dose reductions. Drug exposure as measured by antibody-conjugated MMAE and total antibody was generally dose proportional over all dose levels on both schedules. A total of 6 patients had confirmed partial responses (4 ovarian; 2 pancreatic) with DMOT4039A at 2.4 to 2.8 mg/kg i.v. q3w. DMOT4039A administered at doses up to 2.4 mg/kg q3w and 1.0 mg/kg weekly has a tolerable safety profile and antitumor activity in both pancreatic and ovarian cancer. Mol Cancer Ther; 15(3); 439–47. ©2016 AACR.